Use the following year-end footnote disclosure from Pfizer ‘s 10-K report to answer the following question.

Use the following year-end footnote disclosure from Pfizer‘s 10-K report to answer the following question.

(Millions of Dollars)                                                      2005

Cost of available for sale equity securities             $270

Gross unrealized gains                                                   189

Gross unrealized losses                                                 (12)

Fair value of available for sale equity securities      $447

What amount does Pfizer report on its 2005 balance sheet as available-for-sale equity securities?

Select one:

A. $270 millionB. $447 millionC. $459 millionD. $258 million